MedTrace Logo

STAR-AF:Substrate Versus Trigger Ablation for Reduction of Atrial Fibrillation Trial

NCT00367757 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 107

Last updated 2019-01-30

No results posted yet for this study

Summary

Patient Population: Patients with AF that is symptomatic and refractory to at least one antiarrhythmic medication. Patients must have AF that is paroxysmal (\>4 episodes within 6 months, two episodes \>6 hours within 1 year) or persistent (sustained episode \<6 months terminated by cardioversion or drug).

Purpose: To compare a trigger-based technique (pulmonary vein isolation) to a substrate-based technique (high-frequency, fractionated EGMs) to a combined approach for AF ablation

Conditions

Interventions

PROCEDURE

Ablate AF triggers via PVI

Trigger-based ablation guided by pulmonary vein antrum isolation

PROCEDURE

Substrate via CFAEs

Substrate-based ablation using an approach targeting CFAEs

PROCEDURE

Combined approach for AF ablation

Combined trigger and substrate based approach

Sponsors & Collaborators

  • Abbott Medical Devices

    lead INDUSTRY

Principal Investigators

  • Atul Verma, Dr. · Southlake Regional health Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • Canada
  • Italy
  • Norway
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00367757 on ClinicalTrials.gov